Co-Diagnostics’ PCR test detects mutations in new coronavirus strain

 

• Co-Diagnostics (NASDAQ:CODX) has announced it has completed the principal design work for a PCR test to detect several mutations in the newly detected variant of SARS-CoV-2 known as VUI 202012/01.
• The new test will be a separate product, the company said, confirming that the mutations in the new variant 'are not believed to interfere’ with its existing line of COVID-19 diagnostics.
• Highlighting the ability of its CoPrimer™ platform to reduce false positives, Dwight Egan, CEO of Co-Diagnostics, commented, “the multiplexing capabilities of our CoPrimer platform go hand-in-glove with the technology's applications in detecting small genetic variations in a given gene.’
• The new coronavirus strain, found in the UK, is thought to be highly transmissible than its predecessors, and the British government has imposed tougher social restriction measures to address the fears. 
• https://seekingalpha.com/news/3646713-co-diagnostics-pcr-test-detects-mutations-in-new-coronavirus-strain